Skip to content
OpenCapital
Get started

Evolus EOLS Cash & Equivalents

Cash & Equivalents at other companies

AbbVie logo
AbbVieABBV
$9.39B+81.5%

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×—
Current ratio2×-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's cash & equivalents?
Evolus (EOLS) reported cash & equivalents of $49.79M in Q1 2026.
How has Evolus's cash & equivalents changed year-over-year?
Evolus's cash & equivalents decreased by 26.7% year-over-year, from $67.89M to $49.79M.
What is the long-term trend for Evolus's cash & equivalents?
Over 5 years (2020 to 2025), Evolus's cash & equivalents has grown at a -12.1% compound annual growth rate (CAGR), from $102.56M to $53.83M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.